skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen

Abstract

Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed byC. aurishelps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that aremore » resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.« less

Authors:
ORCiD logo [1]; ORCiD logo [2];  [1]; ORCiD logo [2]; ORCiD logo [2]; ORCiD logo [2]; ORCiD logo [3]; ORCiD logo [4]; ORCiD logo [2]; ORCiD logo [1]
  1. Albert Einstein College of Medicine, Bronx, NY (United States)
  2. Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
  3. Univ. of Szeged, Szeged (Hungary)
  4. Univ. Federal do Rio de Janeiro, Rio de Janeiro (Brazil)
Publication Date:
Research Org.:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org.:
USDOE; National Institutes of Health (NIH)
OSTI Identifier:
1530886
Report Number(s):
PNNL-SA-140174
Journal ID: ISSN 2379-5077
Grant/Contract Number:  
AC0576RL01830; 20391-3/2018/FEKUSTRAT
Resource Type:
Accepted Manuscript
Journal Name:
mSystems
Additional Journal Information:
Journal Volume: 4; Journal Issue: 4; Journal ID: ISSN 2379-5077
Publisher:
American Society for Microbiology
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Zamith-Miranda, Daniel, Heyman, Heino M., Cleare, Levi G., Couvillion, Sneha P., Clair, Geremy C., Bredeweg, Erin L., Gacser, Attila, Nimrichter, Leonardo, Nakayasu, Ernesto S., and Nosanchuk, Joshua D. Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. United States: N. p., 2019. Web. doi:10.1128/mSystems.00257-19.
Zamith-Miranda, Daniel, Heyman, Heino M., Cleare, Levi G., Couvillion, Sneha P., Clair, Geremy C., Bredeweg, Erin L., Gacser, Attila, Nimrichter, Leonardo, Nakayasu, Ernesto S., & Nosanchuk, Joshua D. Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen. United States. doi:10.1128/mSystems.00257-19.
Zamith-Miranda, Daniel, Heyman, Heino M., Cleare, Levi G., Couvillion, Sneha P., Clair, Geremy C., Bredeweg, Erin L., Gacser, Attila, Nimrichter, Leonardo, Nakayasu, Ernesto S., and Nosanchuk, Joshua D. Tue . "Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen". United States. doi:10.1128/mSystems.00257-19. https://www.osti.gov/servlets/purl/1530886.
@article{osti_1530886,
title = {Multi-omics Signature of Candida auris, an Emerging and Multidrug-Resistant Pathogen},
author = {Zamith-Miranda, Daniel and Heyman, Heino M. and Cleare, Levi G. and Couvillion, Sneha P. and Clair, Geremy C. and Bredeweg, Erin L. and Gacser, Attila and Nimrichter, Leonardo and Nakayasu, Ernesto S. and Nosanchuk, Joshua D.},
abstractNote = {Candida auris is a recently described pathogenic fungus that is causing invasive outbreaks on all continents. The fungus is of high concern given the numbers of multidrug-resistant strains that have been isolated in distinct sites across the globe. The fact that its diagnosis is still problematic suggests that the spreading of the pathogen remains underestimated. Notably, the molecular mechanisms of virulence and antifungal resistance employed by this new species are largely unknown. In the present work, we compared two clinical isolates of C. auris with distinct drug susceptibility profiles and a Candida albicans reference strain using a multi-omics approach. Our results show that, despite the distinct drug resistance profile, both C. auris isolates appear to be very similar, albeit with a few notable differences. However, compared to C. albicans both C. auris isolates have major differences regarding their carbon utilization and downstream lipid and protein content, suggesting a multifactorial mechanism of drug resistance. The molecular profile displayed byC. aurishelps to explain the antifungal resistance and virulence phenotypes of this new emerging pathogen. Candida auris was first described in Japan in 2009 and has now been the cause of significant outbreaks across the globe. The high number of isolates that are resistant to one or more antifungals, as well as the high mortality rates from patients with bloodstream infections, has attracted the attention of the medical mycology, infectious disease, and public health communities to this pathogenic fungus. In the current work, we performed a broad multi-omics approach on two clinical isolates isolated in New York, the most affected area in the United States and found that the omic profile of C. auris differs significantly from C. albicans. In addition to our insights into C. auris carbon utilization and lipid and protein content, we believe that the availability of these data will enhance our ability to combat this rapidly emerging pathogenic yeast.},
doi = {10.1128/mSystems.00257-19},
journal = {mSystems},
number = 4,
volume = 4,
place = {United States},
year = {2019},
month = {6}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Save / Share: